Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson Sells 2,500 Shares

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction dated Tuesday, April 15th. The shares were sold at an average price of $106.40, for a total transaction of $266,000.00. Following the completion of the sale, the chief financial officer now owns 168,174 shares of the company’s stock, valued at $17,893,713.60. This trade represents a 1.46 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Gilead Sciences Stock Down 0.4 %

GILD opened at $104.49 on Friday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $119.96. The business has a 50-day moving average of $109.16 and a two-hundred day moving average of $97.45. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The stock has a market capitalization of $130.10 billion, a price-to-earnings ratio of 282.40, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, research analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Stockholders of record on Friday, March 14th were issued a dividend of $0.79 per share. This represents a $3.16 dividend on an annualized basis and a dividend yield of 3.02%. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date was Friday, March 14th. Gilead Sciences’s dividend payout ratio is presently 854.05%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in GILD. Westside Investment Management Inc. increased its position in Gilead Sciences by 3.5% during the 3rd quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company’s stock worth $2,249,000 after purchasing an additional 917 shares in the last quarter. SkyView Investment Advisors LLC increased its position in shares of Gilead Sciences by 5.4% in the third quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company’s stock worth $711,000 after acquiring an additional 435 shares in the last quarter. Pine Valley Investments Ltd Liability Co purchased a new position in shares of Gilead Sciences in the 3rd quarter valued at $209,000. World Investment Advisors LLC lifted its holdings in shares of Gilead Sciences by 33.6% during the 3rd quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company’s stock valued at $2,180,000 after acquiring an additional 6,535 shares in the last quarter. Finally, Arvest Bank Trust Division acquired a new position in shares of Gilead Sciences during the 3rd quarter valued at $9,661,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Oppenheimer lifted their price target on shares of Gilead Sciences from $115.00 to $132.00 and gave the company an “outperform” rating in a research report on Tuesday, March 4th. The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, February 12th. DZ Bank raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $108.00 target price on the stock in a report on Thursday, February 13th. BMO Capital Markets lifted their price target on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Finally, Bank of America increased their price objective on shares of Gilead Sciences from $116.00 to $126.00 and gave the company a “buy” rating in a research note on Wednesday, March 5th. Eleven investment analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $105.12.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.